Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.

1035Background: The PI3K-inhibitor, alpelisib, was approved for the treatment of hormone receptor (HR)-positive, HER2-negative breast cancers with PIK3CA mutations based on findings from the SOLAR-...